MX2007007051A - Nuevos derivados de tiofenpirimidiona sustituida como inhibidores de la 17??-hidroxiesteroide deshidrogenasa. - Google Patents

Nuevos derivados de tiofenpirimidiona sustituida como inhibidores de la 17??-hidroxiesteroide deshidrogenasa.

Info

Publication number
MX2007007051A
MX2007007051A MX2007007051A MX2007007051A MX2007007051A MX 2007007051 A MX2007007051 A MX 2007007051A MX 2007007051 A MX2007007051 A MX 2007007051A MX 2007007051 A MX2007007051 A MX 2007007051A MX 2007007051 A MX2007007051 A MX 2007007051A
Authority
MX
Mexico
Prior art keywords
hydroxysteroid dehydrogenase
inhibitors
novel substituted
thiophenepyrimidinone
derivatives
Prior art date
Application number
MX2007007051A
Other languages
English (en)
Inventor
Leena Hirvela
Pasi Koskimies
Olli Taneli Pentikainen
Pekka Lehtovuori
Josef Messinger
Heinrich-Hubert Thole
Bettina Husen
Bartholomeus Johannes Van Steen
Johanna Kiviniemi
Lila Pirkkala
Pauli Saarenketo
Mikko Unkila
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of MX2007007051A publication Critical patent/MX2007007051A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Esta invencion se refiere a nuevos derivados de tiofenpirimidinona sustituida y a su uso en terapia, especialmente para su uso en el tratamiento y/o prevencion de una enfermedad o trastorno dependiente de hormonas esteroides, tal como enfermedades o trastornos dependientes de hormonas esteroides que requieren la inhibicion de encimas 17??-hidroxiesteroide deshidogenasas.
MX2007007051A 2004-12-13 2004-12-13 Nuevos derivados de tiofenpirimidiona sustituida como inhibidores de la 17??-hidroxiesteroide deshidrogenasa. MX2007007051A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2004/053424 WO2006063615A1 (en) 2004-12-13 2004-12-13 NOVEL SUBSTITUTED THIOPHENEPYRIMIDINONE DERIVATIVES AS INHIBITORS OF 17β-HYDROXYSTEROID DEHYDROGENASE

Publications (1)

Publication Number Publication Date
MX2007007051A true MX2007007051A (es) 2007-06-26

Family

ID=34959788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007007051A MX2007007051A (es) 2004-12-13 2004-12-13 Nuevos derivados de tiofenpirimidiona sustituida como inhibidores de la 17??-hidroxiesteroide deshidrogenasa.

Country Status (13)

Country Link
EP (1) EP1828197B1 (es)
JP (1) JP4686549B2 (es)
CN (1) CN101087793B (es)
AT (1) ATE431351T1 (es)
AU (1) AU2004325692B2 (es)
BR (1) BRPI0419229A (es)
CA (1) CA2590233A1 (es)
DE (1) DE602004021145D1 (es)
ES (1) ES2327240T3 (es)
MX (1) MX2007007051A (es)
NO (1) NO20073610L (es)
PL (1) PL1828197T3 (es)
WO (1) WO2006063615A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
TW201520219A (zh) * 2013-03-12 2015-06-01 Lilly Co Eli 咪唑並吡啶化合物
BR112016015578A2 (pt) 2014-01-03 2017-08-08 Elexopharm Gmbh Inibidores de 17beta-hidroxiesteroide desidrogenases tipo 1 e tipo 2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4054656A (en) * 1975-09-10 1977-10-18 Mead Johnson & Company Thieno[2,3-d]pyrimidine antiallergic agents
JPS62132884A (ja) * 1985-12-05 1987-06-16 Mitsubishi Chem Ind Ltd ２−ベンジルチエノ〔２，３−ｄ〕ピリミジン−４（３Ｈ）−オン誘導体
EP0364598A4 (en) * 1988-03-02 1992-01-15 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof
US5597823A (en) * 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
FI20030393A (fi) * 2003-03-14 2004-09-15 Molekyyliendokrinologian Tutki Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi
US7754709B2 (en) * 2003-06-10 2010-07-13 Solvay Pharmaceuticals Bv Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds
US7465739B2 (en) * 2003-06-10 2008-12-16 Solvay Pharmaceuticals B.V. Compounds and their use in therapy

Also Published As

Publication number Publication date
CN101087793A (zh) 2007-12-12
EP1828197A1 (en) 2007-09-05
BRPI0419229A (pt) 2007-12-18
AU2004325692B2 (en) 2012-01-19
JP2008523117A (ja) 2008-07-03
ATE431351T1 (de) 2009-05-15
CA2590233A1 (en) 2006-06-22
EP1828197B1 (en) 2009-05-13
AU2004325692A1 (en) 2006-06-22
JP4686549B2 (ja) 2011-05-25
WO2006063615A1 (en) 2006-06-22
DE602004021145D1 (de) 2009-06-25
PL1828197T3 (pl) 2009-11-30
ES2327240T3 (es) 2009-10-27
CN101087793B (zh) 2011-09-07
NO20073610L (no) 2007-09-12

Similar Documents

Publication Publication Date Title
TW200509937A (en) Novel compounds and their use in therapy
WO2008034796A3 (en) Estratriene derivatives and their uses as 17beta-hydr0xyster0id dehydrogenase inhibitors
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200609227A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
UA92348C2 (en) 17b-HSD1 AND STS INHIBITORS
MY158162A (en) 5-membered heterocycle-based p38 kinase inhibitors
TW200630096A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
ZA200703002B (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
HK1106131A1 (en) Mitotic kinesin inhibitors and methods of use thereof
WO2005084654A3 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
MX2009005201A (es) Derivados de estratrieno sustituidos como inhibidores de 17beta hsd.
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
MXPA06000705A (es) Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos.
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
NO20073610L (no) Nye substituerte tiofenpyrimidinonderivater som inhibitorer for 17 β-hydroksysteroiddehydrogenase
WO2003094967A3 (en) New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
UA84566C2 (ru) Производные тиофенпиримидинонов и их применение в терапии, фармацевтическая композиция на их основе
EP1597234A4 (en) NEW COMPOUNDS
WO2004012732A3 (en) Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy
RS95204A (en) Combination for the treatment of airway disorders
WO2003075926A8 (en) Use of proton pump inhibitors for the treatment of airway disorders
UA86813C2 (ru) Ингибиторы бета-гидроксистероидной дегидрогеназы типа 1

Legal Events

Date Code Title Description
FG Grant or registration